SCHEMBL6799151

SCHEMBL6799151

COc1cc(OC)cc(C(=O)NCN2CC=CC=C2C2=CCNCC2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.39
MAPT P10636 2/20 0.38
KDM4E B2RXH2 3/20 0.38
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
ATM Q13315 1/20 0.35
NPC1 O15118 2/20 0.35
ALDH1A1 P00352 4/20 0.35
TP53 P04637 1/20 0.35
POLB P06746 1/20 0.35
ALOX15 P16050 1/20 0.35
BRPF1 P55201 1/20 0.35
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
HPGD P15428 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
HTR1D P28221 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6800731 0.78 HTR2C (0.46) ALDH1A1TP53POLBKMT2AMEN1
SCHEMBL6799147 0.69 MAPT (0.38) TDP1MAPTKDM4EGAATSHR
SCHEMBL7098810 0.67 DRD4 (0.35) MAPTNPC1ALDH1A1POLBALOX15
SCHEMBL6211418 0.67 ALDH1A1 (0.45) TDP1KDM4EGAASMN1; SMN2L3MBTL1
SCHEMBL6236536 0.67 MAPT (0.41) MAPTKDM4EGAAL3MBTL1NPC1
SCHEMBL6800083 0.65 HTR6 (0.38) MAPTGAAALDH1A1POLBKMT2A
SCHEMBL6793606 0.65 MAPKAPK2 (0.45) MAPTSMN1; SMN2ATMALDH1A1TP53
SCHEMBL6786592 0.65 HTR2C (0.36) MAPTKDM4EALDH1A1ALOX15HTR2C
SCHEMBL6805208 0.62 MEN1 (0.40) TDP1MAPTKDM4ESMN1; SMN2L3MBTL1
SCHEMBL1077942 0.62 HTR2C (0.37) MAPTKDM4EGAAALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040029887-A1 Acetamides and benzamides that are useful in treating sexual dysfunction ABBOTT LABORATORIES 2004-02-12 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029887-A1 Acetamides and benzamides that are useful in treating sexual dysfunction CATSPER1, CYP19A1, PDE12 TDP1 1720/4885MAPT 3896/4885KDM4E 2903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.